GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearmind Medicine Inc (XCNQ:CMND) » Definitions » Forward PE Ratio

Clearmind Medicine (XCNQ:CMND) Forward PE Ratio : 0.00 (As of May. 11, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Clearmind Medicine Forward PE Ratio?

Clearmind Medicine's Forward PE Ratio for today is 0.00.

Clearmind Medicine's PE Ratio without NRI for today is 0.00.

Clearmind Medicine's PE Ratio for today is 0.00.


Clearmind Medicine Forward PE Ratio Historical Data

The historical data trend for Clearmind Medicine's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearmind Medicine Forward PE Ratio Chart

Clearmind Medicine Annual Data
Trend
Forward PE Ratio

Clearmind Medicine Quarterly Data
Forward PE Ratio

Competitive Comparison of Clearmind Medicine's Forward PE Ratio

For the Biotechnology subindustry, Clearmind Medicine's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clearmind Medicine's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearmind Medicine's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Clearmind Medicine's Forward PE Ratio falls into.



Clearmind Medicine Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Clearmind Medicine  (XCNQ:CMND) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Clearmind Medicine Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Clearmind Medicine's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Clearmind Medicine (XCNQ:CMND) Business Description

Traded in Other Exchanges
Address
101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H 1A5
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.